Priaxon has entered into a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its small molecule drug discovery expertise suited to investigating the modulation of protein-protein interactions (PPIs). PPIs play a role in many cell signaling pathways and cell-surface receptor-ligand interactions associated with disease states.
This collaboration aims to identify and advance candidates from hits to leads for preclinical development, with the goal of developing and commercializing drug candidates. Financial details and therapeutic targets were not disclosed.
"Using the strength of its unique drug discovery platform Priaxplore, Priaxon will develop new small molecule modulators for hard-to-drug PPI targets," said Dr. Juergen Kolb, chief executive officer of Priaxon. "Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward. We are looking forward to working together with the goal to develop small molecule modulators for various protein-protein interaction of high potential."
Priaxon, GSK in Protein Interactions Pact
Published January 8, 2013
Related Breaking News
Related Online Exclusives